Author: admin

DelveInsight’s, “Pancreatic Cancer Pipeline Insight 2025” report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Pancreatic Cancer Pipeline Report to explore emerging therapies, key Pancreatic Cancer Companies, and future Pancreatic Cancer treatment landscapes @ Pancreatic Cancer Pipeline Outlook Report

Key Takeaways from the Pancreatic Cancer Pipeline Report

• In April 2025, Nelson Yee announced phase II clinical study to investigate the efficacy and tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced pancreatic carcinoma (LAPC).
• In April 2025, InxMed (Shanghai) Co. Ltd announced a study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.
• DelveInsight’s Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
• The leading Pancreatic Cancer Companies such as ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
• Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Cancer Treatment Drugs

Pancreatic Cancer Emerging Drugs Profile

• Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

• Devimistat: Cornerstone Pharmaceuticals

CPI-613 (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Cancer progresses because it utilizes the mitochondria – the energy machinery of the cells – to generate the building blocks of the next tumor in order to fuel cancer growth and proliferation. Because it is designed to be highly specific, minimally toxic and effective against a wide variety of cancers, devimistat can be used for recurrent and hard-to-treat cancers, including on a chronic basis; it may also enhance the sensitivity of cancer cells to other treatment modalities, including chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of pancreatic cancer.

• Masitinib: AB Science

Masitinib is a highly selective inhibitor of mast cell which gives therapeutic benefit by impacting on mast cell related remodeling of the tumor microenvironment. Masitinib is being developed in combination with chemotherapies for treatment of malignancies through its immunotherapeutic properties. The increased mast cell activity within the tumor microenvironment can promote disease progression through release of numerous pro-tumoral mediators, down-regulate the immune response to tumors, and modulation of macrophages towards a pro-tumoral state. The inhibition of the mast cell activity results in anti-tumor effect.

• SBP-101: Panbela Therapeutics

Ivospemin (SBP-101) is a proprietary polyamine analogue that, due to its unique chemical structure. It inhibits both S-adenosylmethionine decarboxylase 1 (AMD1) and ornithine decarboxylase 1 (ODC1), two key enzymes in polyamine biosynthesis, lowering intracellular polyamine concentrations and slowing or preventing targeted cell growth and division. Ivospemin provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. The polyamine pathway at complementary junctions alter the disease. In particular, the drug have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system. Currently, the drug is in Phase II/III stage of its development for the treatment of pancreatic cancer.

• TAS-102: Taiho Pharmaceutical Co., Ltd.

TAS-102 (Lonsurf) is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase. The drug is currently in Phase II trial for the pancreatic cancer.

• RAIN-32: Rain Oncology

RAIN-32 (Milademetan), an oral small molecule, inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, and loss of an MDM2 regulator or other mechanism. The company commenced an additional Phase II trial in a multicenter, single arm, open-label, and basket trial evaluating milademetan for the treatment of MDM2-amplified advanced solid tumors (MANTRA-2) including pancreatic cancer.

• IMX-110: Immix Biopharma

IMX-110 is a Tissue-Specific Therapeutic™ built on ImmixBio’s TME Normalization™ Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio’s TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110’s TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).

The Pancreatic Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
• Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Pancreatic Cancer Drugs

Pancreatic Cancer Companies

ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pancreatic Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Pancreatic Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pancreatic Cancer Market Drivers and Barriers

Scope of the Pancreatic Cancer Pipeline Report

• Coverage- Global
• Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
• Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.

Which companies are leading the race in Pancreatic Cancer drug development? Find out in DelveInsight’s exclusive Pancreatic Cancer Pipeline Report—access it now! @ Pancreatic Cancer Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Pancreatic Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pamrevlumab: FibroGen
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Niraparib: Innovent Biologics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. CT041: CARsgen Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ONC 212: Oncoceutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Cancer Key Companies
21. Pancreatic Cancer Key Products
22. Pancreatic Cancer- Unmet Needs
23. Pancreatic Cancer- Market Drivers and Barriers
24. Pancreatic Cancer- Future Perspectives and Conclusion
25. Pancreatic Cancer Analyst Views
26. Pancreatic Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Cancer Pipeline Appears Robust With 290+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Neuroendocrine tumors Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Neuroendocrine tumors pipeline landscape. It covers the Neuroendocrine Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Neuroendocrine Tumors Pipeline Outlook

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

• In April 2025, Boehringer Ingelheim announced a study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.
• DelveInsight’s Neuroendocrine Tumors pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Neuroendocrine Tumors treatment.
• The leading Neuroendocrine Tumors Companies such as RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals and others.
• Promising Neuroendocrine Tumors Pipeline Therapies such as lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.

Stay ahead with the most recent pipeline outlook for Neuroendocrine Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Treatment Drugs

Neuroendocrine Tumors Emerging Drugs Profile

• RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors. Currently, the drug is in the Phase III stage of development to treat neuroendocrine tumors.

• CAM2029: Camurus

CAM2029 is a long-acting subcutaneous depot of octreotide under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. Currently, the drug is in the Phase III stage of its development for the treatment of gastroentero pancreatic neuroendocrine tumors.

• Ramucirumab: Eli Lilly and Company

Ramucirumab is a fully human IgG1 monoclonal antibody receptor antagonist designed to bind the extracellular domain of vascular endothelial growth factor (VEGF) receptor-2, thereby blocking the interaction of VEGF ligands (VEGF-A, VEGF-C, and VEGF-D) and inhibiting receptor activation. VEGF receptor-2 is considered a primary mediator of angiogenesis. When activated by VEGF ligands, VEGF receptor-2 promotes endothelial cell proliferation and survival, migration, and vascular permeability. Ramucirumab, which Lilly gained through its 2008 acquisition of ImClone Systems, is being investigated in clinical trials as monotherapy and in combination with other anticancer therapies for the treatment of multiple types of cancer. Currently, the drug is in the Phase II stage of its development for the treatment of neuroendocrine tumors.

• Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

• ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

The Neuroendocrine Tumors Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
• Neuroendocrine Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market

Explore groundbreaking therapies and clinical trials in the Neuroendocrine Tumors Pipeline. Access DelveInsight’s detailed report now! @ New Neuroendocrine Tumors Drugs

Neuroendocrine Tumors Companies

RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals and others.

Neuroendocrine tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Neuroendocrine Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers

Scope of the Neuroendocrine Tumors Pipeline Report

• Coverage- Global
• Neuroendocrine Tumors Companies- RayzeBio, Inc., Camurus, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals and others.
• Neuroendocrine Tumors Pipeline Therapies- lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.
• Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Neuroendocrine Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Neuroendocrine Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. RYZ101: RayzeBio, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Ramucirumab: Eli Lilly and Company
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ADCT-701: ADC Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Neuroendocrine Tumors Key Companies
21. Neuroendocrine Tumors Key Products
22. Neuroendocrine Tumors- Unmet Needs
23. Neuroendocrine Tumors- Market Drivers and Barriers
24. Neuroendocrine Tumors- Future Perspectives and Conclusion
25. Neuroendocrine Tumors Analyst Views
26. Neuroendocrine Tumors Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuroendocrine Tumors Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Merkel Cell Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Merkel Cell Carcinoma pipeline landscape. It covers the Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in the competitive pharmaceutical landscape with in-depth Pipeline Insights! Discover the latest advancements, key Merkel Cell Carcinoma Companies driving innovation, and the most promising Emerging Drugs shaping the future of treatment. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Merkel Cell Carcinoma Pipeline Outlook Report

Key Takeaways from the Merkel Cell Carcinoma Pipeline Insights Report

• In April 2025, Replimiune Inc. announced a phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients. Patients will participate up to approximately 3 years including a 28-day screening period, up to approximately 1 year treatment period, and a 2-year follow-up period.
• In April 2025, Ariceum Therapeutics GmbH conducted a study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
• In April 2025, Aulos Bioscience, Inc. announced a phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin is determined, AU-007 plus aldesleukin will also be administered with avelumab or nivolumab.
• DelveInsight’s Merkel Cell Carcinoma pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Merkel Cell Carcinoma treatment.
• The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
• Promising Merkel Cell Carcinoma Therapies such as Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.

Uncover Merkel Cell Carcinoma groundbreaking developments in the drug pipeline with our latest report! Gain exclusive insights into Merkel Cell Carcinoma Clinical Trials, regulatory updates, and Emerging Drugs across multiple therapeutic areas. Learn how leading Merkel Cell Carcinoma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Merkel Cell Carcinoma Clinical Trials Assessment

Merkel Cell Carcinoma Emerging Drugs Profile

• Domatinostat: 4SC

Domatinostat is an orally administered histone deacetylase (HDAC) inhibitor with a unique mode of action that was designed to strengthen the body’s own anti-tumor immune response. Domatinostat “opens” the tumor microenvironment and encourages infiltration of immune cells into the tumor. To advance the development program, 4SC has also signed a drug supply agreement with Merck KGaA for avelumab (anti-PD-L1 antibody) to conduct a Phase II clinical trial of domatinostat in combination with avelumab in advanced-stage Merkel cell carcinoma (MCC) patients progressing on previous anti-PD-(L)1 monotherapy (MERKLIN 2).

• Cavrotolimod: Exicure

Cavrotolimod (AST-008) is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. During the first half of 2019, five clinical trial sites were opened and began dosing patients for the Phase I/II clinical trial. The Phase 1b stage was an open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod (AST-008) injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). Exicure initiated the Phase II stage of the clinical trial with dose-expansion cohorts of intratumoral cavrotolimod in combination with approved checkpoint inhibitors to treat two cohorts of patients with locally advanced or metastatic MCC or CSCC.

The Merkel Cell Carcinoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Merkel Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Merkel Cell Carcinoma Treatment.
• Merkel Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Merkel Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Merkel Cell Carcinoma market.

Explore the dynamic world of drug development with our latest Merkel Cell Carcinoma Pipeline Insights report! From early-stage research to late-phase Merkel Cell Carcinoma Clinical Trials, our analysis covers key Merkel Cell Carcinoma Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Merkel Cell Carcinoma Treatment Drugs

Merkel Cell Carcinoma Companies

ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.

Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Merkel Cell Carcinoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Stay updated with the latest Merkel Cell Carcinoma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Merkel Cell Carcinoma Pipeline Report

• Coverage- Global
• Merkel Cell Carcinoma Companies- ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
• Merkel Cell Carcinoma Therapies- Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.
• Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Merkel Cell Carcinoma Emerging Drugs are set to revolutionize treatment landscapes? Which Merkel Cell Carcinoma Companies are leading the way in drug discovery? Find answers in our latest Merkel Cell Carcinoma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Merkel Cell Carcinoma Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Merkel Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mid Stage Products (Phase II)
7. Domatinostat: 4SC
8. Drug profiles in the detailed report…..
9. Early Stage Products (Phase I/II)
10. XmAb18087: Xencor
11. Drug profiles in the detailed report…..
12. Preclinical stage products
13. SNS-401-NG: Sensei Biotherapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Merkel Cell Carcinoma Key Companies
17. Merkel Cell Carcinoma Key Products
18. Merkel Cell Carcinoma- Unmet Needs
19. Merkel Cell Carcinoma- Market Drivers and Barriers
20. Merkel Cell Carcinoma- Future Perspectives and Conclusion
21. Merkel Cell Carcinoma Analyst Views
22. Merkel Cell Carcinoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/merkel-cell-carcinoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Merkel Cell Carcinoma Pipeline Appears Robust With 14+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape. Click here to read more @ Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Renal Cell Carcinoma Pipeline Report

• In May 2025, Merck Sharp & Dohme LLC announced a study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in Part 1.
• In May 2025, Karie Runcie announced a Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of XL092 alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
• DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
• The leading Renal Cell Carcinoma Companies such as AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
• Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.

Discover groundbreaking developments in Renal Cell Carcinoma therapies! Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Renal Cell Carcinoma Clinical Trials Assessment

Renal Cell Carcinoma Emerging Drugs Profile

• CM082: Betta Pharmaceuticals

CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma.

• TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.

• IPI-549: Infinity Pharmaceuticals

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.

• CMN-001: ColImmune

Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.

The Renal Cell Carcinoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cell Carcinoma Treatment.
• Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cell Carcinoma market.

Stay informed about the Renal Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs

Renal Cell Carcinoma Companies

AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Renal Cell Carcinoma Products have been categorized under various Molecule types such as

• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
• Product Type

Transform your understanding of the Renal Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Renal Cell Carcinoma Pipeline Report

• Coverage- Global
• Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
• Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
• Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies

Table of Content

1. Introduction
2. Renal Cell Carcinoma Executive Summary
3. Renal Cell Carcinoma: Overview
4. Renal Cell Carcinoma Pipeline Therapeutics
5. Renal Cell Carcinoma Therapeutic Assessment
6. Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Renal Cell Carcinoma Collaboration Deals
9. Late Stage Products (Phase III)
10. TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. IPI-549: Infinity Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AVB-S6-500: Aravive Inc.
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Renal Cell Carcinoma Key Companies
23. Renal Cell Carcinoma Key Products
24. Renal Cell Carcinoma – Unmet Needs
25. Renal Cell Carcinoma – Market Drivers and Barriers
26. Renal Cell Carcinoma – Future Perspectives and Conclusion
27. Renal Cell Carcinoma Analyst Views
28. Renal Cell Carcinoma Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Lymphocytic Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Small Lymphocytic Lymphoma Pipeline Report to explore emerging therapies, key Small Lymphocytic Lymphoma Companies, and future Small Lymphocytic Lymphoma treatment landscapes @ Small Lymphocytic Lymphoma Pipeline Outlook Report

Key Takeaways from the Small Lymphocytic Lymphoma Pipeline Report

• In May 2025, Merck Sharp & Dohme LLC announced a study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
• In May 2025, AbbVie announced a phase 2 study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).
• In May 2025, BeiGene announced a study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
• DelveInsight’s Small Lymphocytic Lymphoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Small Lymphocytic Lymphoma treatment.
• The leading Small Lymphocytic Lymphoma Companies such as Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others.
• Promising Small Lymphocytic Lymphoma Therapies such as ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.

Discover how the Small Lymphocytic Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth Small Lymphocytic Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Small Lymphocytic Lymphoma Clinical Trials and Studies

Small Lymphocytic Lymphoma Emerging Drugs Profile

• TQ-B3525: Chia Tai Tianqing Pharmaceutical Group

TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

• LOXO-305: Loxo Oncology

Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and marginal zone lymphoma. Currently available BTK inhibitors irreversibly inhibit BTK and the long-term efficacy of these therapies can be limited by acquired resistance. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. Pirtobrutinib is currently being studied in multiple clinical trials. Safety and efficacy have not been established for the uses being studied.

• IOV 2001: Iovance Biotherapeutics

IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

The Small Lymphocytic Lymphoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Small Lymphocytic Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Lymphocytic Lymphoma Treatment.
• Small Lymphocytic Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Small Lymphocytic Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Lymphocytic Lymphoma market.

Get a detailed analysis of the latest innovations in the Small Lymphocytic Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Small Lymphocytic Lymphoma Unmet Needs

Small Lymphocytic Lymphoma Companies

Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics and others.

Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Small Lymphocytic Lymphoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming Small Lymphocytic Lymphoma Therapies and key Small Lymphocytic Lymphoma Developments @ Small Lymphocytic Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Small Lymphocytic Lymphoma Pipeline Report

• Coverage- Global
• Small Lymphocytic Lymphoma Companies- Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics and others.
• Small Lymphocytic Lymphoma Therapies- ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.
• Small Lymphocytic Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Small Lymphocytic Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Small Lymphocytic Lymphoma drug development? Find out in DelveInsight’s exclusive Small Lymphocytic Lymphoma Pipeline Report—access it now! @ Small Lymphocytic Lymphoma Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Small Lymphocytic Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Small Lymphocytic Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. LOXO-305: Loxo Oncology
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase I/II)
14. TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Small Lymphocytic Lymphoma Key Companies
21. Small Lymphocytic Lymphoma Key Products
22. Small Lymphocytic Lymphoma – Unmet Needs
23. Small Lymphocytic Lymphoma – Market Drivers and Barriers
24. Small Lymphocytic Lymphoma – Future Perspectives and Conclusion
25. Small Lymphocytic Lymphoma Analyst Views
26. Small Lymphocytic Lymphoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/small-lymphocytic-lymphoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small lymphocytic lymphoma Pipeline Appears Robust With 80+ Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Hepatocellular Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hepatocellular Carcinoma Treatment Landscape. Click here to read more @ Hepatocellular Carcinoma Pipeline Outlook

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

• In May 2025, Coherus Biosciences Inc. announced a phase 2 trial composed of an open label Lead-In followed by a Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
• DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
• The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
• Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others

Discover groundbreaking developments in Hepatocellular Carcinoma therapies! Gain in-depth knowledge of key Hepatocellular Carcinoma clinical trials, emerging drugs, and market opportunities @ Hepatocellular Carcinoma Clinical Trials Assessment

Hepatocellular Carcinoma Emerging Drugs

• Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Hepatocellular Carcinoma and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.

• SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.

• Porustobart: Harbour BioMed

Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

• Fisogatinib: CStone Pharmaceuticals

Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.

• STP705: Sirnaomics

STP705 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-β1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various Hepatocellular Carcinomas. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.

The Hepatocellular Carcinoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma Treatment.
• Hepatocellular Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatocellular Carcinoma market.

Stay informed about the Hepatocellular Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hepatocellular Carcinoma Unmet Needs

Hepatocellular Carcinoma Companies

Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Transform your understanding of the Hepatocellular Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Hepatocellular Carcinoma Pipeline Report

• Coverage- Global
• Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
• Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others
• Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Hepatocellular Carcinoma Pipeline Analysis Today! @ Hepatocellular Carcinoma Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Hepatocellular Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hepatocellular Carcinoma- DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Namodenoson: Can-Fite BioPharma

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. SRF388: Surface Oncology

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. STP705: Sirnaomics

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Hepatocellular Carcinoma Key Companies

21. Hepatocellular Carcinoma Key Products

22. Hepatocellular Carcinoma- Unmet Needs

23. Hepatocellular Carcinoma- Market Drivers and Barriers

24. Hepatocellular Carcinoma- Future Perspectives and Conclusion

25. Hepatocellular Carcinoma Analyst Views

26. Hepatocellular Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight